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Abstract: Overweight and obesity are important risk factors for type 2 diabetes (T2D). Moving towards
healthier diets, namely, diets rich in bioactive compounds, could decrease the odds of suffering
T2D. However, those individuals with high body mass index (BMI) may have altered absorption
or metabolism of some nutrients and dietary components, including polyphenols. Therefore, we
aimed to assess whether high intakes of some classes of polyphenols are associated with T2D in a
population with metabolic syndrome and how these associations depend on BMI and sex. This baseline
cross-sectional analysis includes 6633 participants from the PREDIMED-Plus trial. Polyphenol intakes
were calculated from food frequency questionnaires (FFQ). Cox regression models with constant
time at risk and robust variance estimators were used to estimate the prevalence ratios (PRs) for
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polyphenol intake and T2D prevalence using the lowest quartile as the reference group. Analyses
were stratified by sex and BMI groups (overweight and obese) to evaluate potential effect modification.
Catechins, proanthocyanidins, hydroxybenzoic acids, and lignans were inversely associated with T2D.
Hydroxycinnamic acids were directly related in men. These associations were different depending on
sex and BMI, that is, women and overweight obtained stronger inverse associations.
Keywords: diet; obesity; flavonoids; catechins; proanthocyanidins; hydroxybenzoic acids;
hydroxycinnamic acids; lignans; phenolic acids
1. Introduction
The number of people with diabetes has been increasing over the past few decades and the
estimations for the near future are not encouraging. Currently, 8.5% of adults have diabetes worldwide,
type 2 diabetes (T2D) being the most prevalent type. People with T2D have increased odds of premature
death and are more likely to have myocardial infarction or angina, stroke, kidney failure, peripheral
artery disease, vision loss, and neuropathy. Therefore, T2D may be considered a global public health
problem with vast economic consequences [1].
Unlike type 1 diabetes, T2D can be prevented through different approaches, namely, exercising
regularly, avoiding smoking, keeping weight under control, and adhering to a healthy diet. There
is compelling evidence from prospective observational studies and clinical trials that individual
nutrients, foods, and dietary patterns are crucial in the prevention and management of T2D. It is
well known that plant-based diets including whole grains, fruits, vegetables, legumes, and nuts as
well as moderate alcohol consumption have been associated with lowering the risk of T2D, whereas
diets rich in refined grains, red or processed meats, and sugar-sweetened beverages increase the
risk [2]. Plant foods are usually rich in polyphenols, a large and heterogeneous group of bioactive
compounds that constitute the first source of antioxidants in the diet. Polyphenols are usually classified
according to their structure into two main groups—flavonoids and non-flavonoids. The flavonoid
group, with C6–C3–C6 structured compounds, includes flavones, flavonols, theaflavins, catechins,
proanthocyanidins (polymeric forms), flavanones, anthocyanidins, and isoflavones. Phenolic acids,
lignans, and stilbenes belong to the non-flavonoid group. High polyphenol intake has been associated
with a reduced incidence of T2D in epidemiological studies [3], and better metabolic control in those
participants with T2D. Some of the mechanisms by which dietary polyphenols and their metabolites
exert their effects have been elucidated but others are still unknown [4].
Overweight and obese individuals are at higher risk of T2D than lean ones, therefore it seems that
they would particularly benefit from polyphenol intake. However, some literature suggest that those
with higher body mass index (BMI) may have altered absorption or metabolism of some nutrients and
dietary components, including polyphenols [5,6].
Due to the heterogeneity of polyphenols, and to understand their antidiabetic properties, it is
necessary to study them considering the different groups separately, because they have different
absorption and metabolism [7]. Epidemiological and clinical studies have usually been focused on
some polyphenolic groups, but comprehensive studies are still scarce. Moreover, to our knowledge,
no previous studies have examined the associations between the intake of all polyphenolic groups
and subgroups and the risk of T2D stratifying by sex and BMI. Therefore, our aim was to examine the
hypothesis that higher intakes of some classes of polyphenols are associated with T2D in a population
with metabolic syndrome and these associations depend on sex and BMI.
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2. Materials and Methods
2.1. Study Design and Population
The present study was designed as a baseline cross-sectional analysis in the PREDIMED-Plus
trial, a six-year parallel-group, multicenter, randomized, lifestyle intervention study for the primary
prevention of cardiovascular disease involving 6874 participants recruited in 23 Spanish recruiting
centers from October 2013 to December 2016. Eligible participants were men (aged 55–75 years) and
women (aged 60–75 years) with a BMI between 27 and 40 kg/m2 who met, at least, three components
of the metabolic syndrome (updated harmonized criteria of the International Diabetes Federation and
the American Heart Association and National Heart, Lung, and Blood Institute).
Details on the PREDIMED-Plus protocol can be found at http://predimedplus.com. The selection
and the description of the studied sample have been previously reported [8]. The PREDIMED-Plus
trial was registered at the International Standard Randomized Controlled Trial (ISRCTN89898870;
registration date, 24 July 2014). All participants provided written informed consent, and the study
protocol and procedures were approved according to the ethical standards of the Declaration of Helsinki
by all the participating institutions: CEI Provincial de Málaga, CEI de los Hospitales Universitarios
Virgen Macarena y Virgen del Rocío, CEI de la Universidad de Navarra, CEI de las Illes Balears, CEIC
del Hospital Clínic de Barcelona, CEIC del Parc de Salut Mar, CEIC del Hospital Universitari Sant
Joan de Reus, CEI del Hospital Universitario San Cecilio, CEIC de la Fundación Jiménez Díaz, CEIC
Euskadi, CEI en Humanos de la Universidad de Valencia, CEIC del Hospital Universitario de Gran
Canaria Doctor Negrín, CEIC del Hospital Universitario de Bellvitge, CEI de Córdoba, CEI de Instituto
Madrileño De Estudios Avanzados, CEIC del Hospital Clínico San Carlos, CEI Provincial de Málaga,
CEI de las Illes Balears, CCEI de la Investigación Biomédica de Andalucía and CEIC de León. The
code of the Etical Committe aproval of the Coordinated Center (CEIC del Hospital Universitari Sant
Joan de Reus) is 13-07-25/7proj2 (aproval date: 30/07/2013).
After the exclusion of 53 participants with missing baseline dietary data and 188 with extreme
energy intakes (<500 or >3500 for women and <800 and >4000 for men) [9], 6633 participants were
available for the present analysis.
2.2. Dietary Assessment and Polyphenol Intake
At baseline, participants filled out a validated 143-item semi-quantitative food frequency
questionnaire (FFQ) [10] under the supervision of registered dietitians, from which total energy and
nutrient intake were calculated on the basis of Spanish food composition tables [11,12]. Additionally,
they were asked to fill out a 17-point score questionnaire measuring adherence to an energy-restricted
traditional Mediterranean diet (MedDiet), an updated version of the 14-point score questionnaire used
in the PREDIMED trial [13].
The 143-item FFQ was also used to calculate polyphenol intake together with the Phenol-Explorer
database (www.phenol-explorer.eu). The validity of this particular FFQ to assess total polyphenol
intake was tested in both clinical and cross-sectional studies [14,15]. Individual polyphenol intakes
were obtained by multiplying the content of each polyphenol in each food item with polyphenols
(mg/g) by the daily consumption of this food item (g/day) and then summing the product across all
food items. Then, polyphenol subclasses were adjusted for total energy intake using the residual
method [9]. After stratification by sex and BMI groups, namely, overweight (BMI < 30 kg/m2) and
obese (BMI ≥ 30 kg/m2), polyphenol intakes were divided in quartiles.
2.3. Ascertainment of T2D
For the present analysis, the main endpoint was the prevalence of T2D, defined as previous
clinical diagnosis of T2D, or glycated hemoglobin (HbA1c) ≥ 6.5%, or use of antidiabetic medication at
baseline, or fasting plasma glucose > 126 mg/dl in both the screening visit and baseline visit.
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2.4. Assessment of Covariates
Participants filled out a general questionnaire to provide data on lifestyle habits, education,
concurrent diseases, and medication use. Physical activity was measured by a short Minnesota Leisure
Time Physical Activity Questionnaire validated for the Spanish population [16]. Height and weight
were measured by trained staff. BMI was calculated as weight in kilograms by the square of height in
meters. After an overnight fasting, blood samples were collected. Serum glucose, triglyceride, as well
as total and high-density lipoprotein (HDL) cholesterol levels were measured by routine laboratory
tests using standard enzymatic methods.
2.5. Statistical Methods
Baseline characteristics according to quartiles of total polyphenol intake are presented as means
(±SD) for quantitative variables and frequencies for categorical variables. One-factor ANOVA tests
were used to assess the differences between quartiles of polyphenol consumption and chi-squared
tests for categorical variables.
We used Cox regression models with constant time at risk and robust variance estimators to obtain
the prevalence ratios (PRs) for polyphenol intake and T2D prevalence using the lowest quartile as the
reference group [17]. We ran stratified analyses for sex and BMI groups (overweight and obese) to
evaluate potential effect modification.
In multivariate models, we adjusted for age (continuous), smoking status (never, current,
or former), physical activity (quintiles), and education (primary education, secondary education,
academic/graduate) in model 1. In the fully adjusted model, we additionally adjusted for energy intake
(continuous) as well as consumption of refined cereals and animal products (derived from the 17-point
questionnaire) and of distilled beverages and liquors, sugar, soft drinks, cookies, and pastries (in g/day
derived from the FFQ). All models were stratified by the recruiting center.
Interaction effect was calculated comparing the models, with and without the interaction term,
with likelihood-ratio tests after estimation. We tested for linear trends across categories of polyphenol
intake by assigning each participant the median value for each category and modelling this value
as a continuous variable. Statistical analyses were conducted using STATA software (version 15.1;
StataCorp, College Station, TX, USA). All t-tests were two-sided and p-values below 0.05 were
considered significant.
3. Results
The present study was conducted on 6633 participants from the PREDIMED-Plus cohort, 51.6%
men, with a mean age of 65.0 ± 4.9 years. Of these, 2042 had T2D at baseline (30.8%). Mean total
polyphenol intake was 846 ± 275 mg/day. Approximately 58% corresponded to flavonoids, 33% were
phenolic acids, and the rest were stilbenes, lignans, and other polyphenols. The flavonoid group was
mainly composed of proanthocyanidins (205 ± 175 mg/day), flavanones (86 ± 75 mg/day), flavones
(72 ± 45 mg/day), flavonols (54 ± 22 mg/day), anthocyanidins (44 ± 36 mg/day), and catechins (28 ±
22 mg/day). Other flavonoid subclasses, namely, chalcones, dihydrochalcones and dihydroflavonols,
theaflavins, and isoflavonoids, contributed less than 1% and were not considered in the analyses. Within
phenolic acids, hydroxycinnamic acids were the main subclass (>90%) and hydroxybenzoic acids
followed them with 6%. Other minor phenolic acids were also not considered. Intake of energy-adjusted
polyphenols by sex and BMI group is shown in Table S1, Supplementary Materials. Men tended
to have higher intakes of total polyphenols and total phenolic acids, as well as anthocyanidins,
catechins, hydroxycinnamic and hydroxybenzoic acids, stilbenes, and lignans, whereas women had
higher intakes of flavones. Considering BMI groups, overweight men had higher intakes of total
flavonoids and proanthocyanidins, but lower intakes of total phenolic acids and hydroxycinnamic
acids compared to obese men. On the other hand, women within the overweight group had higher
intakes of hydroxybenzoic acids and stilbenes but lower intakes of hydroxycinnamic acids.
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Table 1 shows baseline participant characteristics by quartiles of energy-adjusted total polyphenol
intake. At baseline, participants in the highest quartile were more likely to be men, physically
active, smokers and former smokers, and with a higher education level. The same characteristics are
summarized according to sex and BMI groups in Table S2, Supplementary Materials. In this cohort,
men were younger (because of the inclusion criteria), had higher BMI, were more physically active,
and were more highly educated than women. Within the group of men, there were more smokers, the
prevalence of T2D was higher, as well of T2D treatment users. Their fasting glucose levels were more
elevated, but not HbA1c. Overweight men and women had lower prevalence of T2D (although not
significant in the case of men), lower fasting glucose levels, were more physically active, and were
more educated. Moreover, overweight men were older, and overweight women used less metformin,
had lower levels of HbA1c, and smoked more.
Table 1. Baseline characteristics by quartiles of energy-adjusted polyphenol intake (n = 6633).
Characteristics Quartile 1 Quartile 2 Quartile 3 Quartile 4 p-Value
n 1659 1658 1658 1658
Total polyphenols (mg/day),
median (min–max) 561 (73–662) 736 (663–812) 896 (813–994) 1146 (995–3377)
Sex, males, n (%) 775 (46.7) 871 (47.5) 775 (53.3) 679 (59.1) <0.001
Age (years) 64.9 ± 4.9 65.0 ± 4.8 65.0 ± 4.9 65.1 ± 5.0 0.65
Body mass index (kg/m2) 32.6 ± 3.5 32.6 ± 3.5 32.6 ± 3.5 32.4 ± 3.3 0.07
Diabetic, n (%) 489 (29.5) 523 (31.5) 519 (31.3) 511 (30.8) 0.57
Insulin, n (%) 82 (4.9) 88 (5.3) 76 (4.6) 68 (4.1) 0.40
Metformin, n (%) 356 (21.5) 405 (24.4) 394 (23.8) 389 (23.5) 0.21
Other glucose lowering
medication, n (%) 306 (18.4) 342 (20.6) 341 (20.6) 336 (20.3) 0.35
Fasting glucose (mg/dL) 113 ± 29 113 ± 29 114 ± 31 113 ± 28 0.59
Glycated hemoglobin (mmol/L) 6.1 ± 0.9 6.1 ± 0.8 6.1 ± 1.0 6.1 ± 0.8 0.54
Physical activity,
(METS·min/week) 2252 ± 2216 2434 ± 2249 2437 ± 2275 2733 ± 2435 <0.001
Smoking status, n (%)
Smoker 231 (13.9) 235 (14.2) 242 (14.6) 258 (15.6)
<0.001Former, >1 year 623 (37.6) 642 (38.7) 709 (42.8) 762 (46.0)
Never 804 (48.5) 780 (47.0) 706 (42.6) 638 (38.5)
Education level, n (%)
High 308 (18.6) 319 (19.2) 363 (21.9) 464 (28.0)
<0.001Medium 484 (29.2) 467 (28.2) 485 (29.3) 477 (28.8)
Low 867 (52.3) 872 (52.6) 810 (48.8) 717 (43.2)
Values are frequencies and percentages for categorical variables or means ± SD for continuous variables, except for
polyphenol intake which is represented by medians (min–max). p-values were calculated by chi-squared tests for
categorical variables and ANOVA for continuous variables.
In Table 2, we summarize nutrient and main food group consumption according to energy-adjusted
quartiles of polyphenol intake. Those in the fourth quartile tended to have a healthier diet in general,
with higher consumption of fruits, vegetables, and nuts, and lower consumption of cereals, dairy
products, meat, and sugar. They also presented higher intake of total carbohydrates and fiber, and
lower intake of fatty acids compared to those in the reference quartile. However, they also had greater
intake of alcohol, soft drinks, and cookies, pastries, and sweets, and lower consumption of olive oil.
Nutrient composition of the diet and main food items according to sex and BMI groups are presented
in Table S3, Supplementary Materials. There were no significant differences in total caloric intake
between overweight and obese, men or women. Generally, women had healthier diets (higher score
in the 17-point MedDiet questionnaire), with greater consumption of fiber, vegetables, dairies, and
fish, and less alcohol. No differences were observed for legumes and nuts between sex. Obese men
also reported to consume more meat, but less sugar than overweight men. On the other hand, obese
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women had poorer Mediterranean diet adherence, with less consumption of polyunsaturated fatty
acids (PUFAs) and nuts, and less alcohol.
Table 2. Main dietary nutrient and food consumption according to quartiles of energy-adjusted
polyphenol intake at baseline (n = 6633).
Nutrients and Foods Quartile 1 Quartile 2 Quartile 3 Quartile 4 p-Value
n 1659 1658 1658 1658
Total energy (kJ/day) (kcal/day) 10272 ± 2293(2454 ± 548)
9481 ± 2256
(2265 ± 539)
9670 ± 2293
(2310 ± 548)
10180 ± 2294
(2432 ± 548) <0.001
Carbohydrates (g/day) 246 ± 75 229 ± 70 237 ± 71 251 ± 73 <0.001
Fiber (g/day) 23 ± 7 25 ± 8 27 ± 8 30 ± 10 <0.001
Proteins (g/day) 100 ± 22 95 ± 22 96 ± 22 99 ± 22 <0.001
MUFAs (g/day) 57 ± 16 52 ± 16 52 ± 16 54 ± 16 <0.001
PUFAs (g/day) 18 ± 7 16 ± 6 16 ± 6 17 ± 6 <0.001
SFAs (g/day) 28 ± 9 25 ± 8 25 ± 8 26 ± 9 <0.001
Alcohol (g/day) 10 ± 14 10 ± 14 11 ± 14 14 ± 17 <0.001
17-point MedDiet score 7.7 ± 2.5 8.5 ± 2.6 8.7 ± 2.6 9.2 ± 2.7 <0.001
Food items (g/day)
Vegetables 299 ± 125 319 ± 129 336 ± 134 357 ± 160 <0.001
Fruits 262 ± 146 324 ± 160 381 ± 181 470 ± 261 <0.001
Legumes 21 ± 11 21 ± 11 20 ± 11 21 ± 12 0.23
Cereals 164 ± 83 144 ± 74 147 ± 77 146 ± 77 <0.001
Dairy 358 ± 205 338 ± 193 341 ± 196 347 ± 211 0.02
Meat 160 ± 62 145 ± 58 143 ± 56 143 ± 56 <0.001
Olive oil 43 ± 18 39 ± 17 39 ± 16 39 ± 16 <0.001
Fish 101 ± 50 101 ± 48 102 ± 45 105 ± 47 0.05
Nuts 13 ± 16 14 ± 17 15 ± 17 17 ± 19 <0.001
Cookies, pastries, and sweets 27 ± 31 23 ± 28 25 ± 28 32 ± 32 <0.001
Sugar 8 ± 13 7 ± 11 6 ± 11 6 ± 12 <0.001
Soft drinks 31 ± 82 20 ± 56 20 ± 62 16 ± 51 <0.001
Values are means ± SD. p-values were calculated by ANOVA tests. Monounsaturated fatty acids, MUFAs;
polyunsaturated fatty acids, PUFAs; saturated fatty acids, SFAs; Mediterranean diet, MedDiet.
We performed Cox proportional models with constant time to study the association between T2D
prevalence and quartiles of the following main polyphenol groups: flavonoids (proanthocyanidins,
flavanones, flavones, flavonols, anthocyanidins, and catechins), phenolic acids (hydroxycinnamic and
hydroxybenzoic acids), stilbenes, and lignans. The results of the fully adjusted model comparing the
fourth versus the first quartiles for men and women are shown in Figure 1. Significant inverse and linear
associations were found for catechins, hydroxybenzoic acids, and lignans for both men and women.
Proanthocyanidin intake was also inversely associated with T2D, but in men the linearity was not
significant. These associations were always stronger for women. On the other hand, hydroxycinnamic
acids showed a strong direct association with T2D prevalence in men, but marginally significant in the
case of women.
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Because weight is an important risk factor for T2D, we also performed the same analysis but 
dividing the population in two groups according to the BMI—overweight (BMI < 30 kg/m2), and 
obese (BMI ≥ 30 kg/m2). In our cohort, three out of four participants were obese. The prevalence of 
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Table 3. Prevalence ratio (PR) and confidence interval (CI) for prevalence of T2D and groups of energy-adjusted polyphenol intake by sex and BMI.
Men Women
Overweight (BMI < 30) Obese (BMI ≥ 30) Overweight (BMI < 30) Obese (BMI ≥ 30)
n = 971 (314 cases, 32%) n = 2453 (828 cases, 34%) n = 802 (194 cases, 24%) n = 2407 (706 cases, 29%)
Q4 vs. Q1 p-value p-trend Q4 vs. Q1 p-value p-trend Q4 vs. Q1 p-value p-trend Q4 vs. Q1 p-value p-trend
Proanthocyanidins
Mean intake,
mg/day 458.9 vs. 63.5 434.2 vs. 53.1 435.3 vs. 57.9 415.3 vs. 51.4
Cases 69 vs. 87 179 vs. 188 33 vs. 54 153 vs. 190
PR
(CI)—unadjusted 0.81 (0.62–1.05) 0.11 0.18 0.96 (0.67–1.14) 0.67 0.79 0.62 (0.42–0.91) 0.02 0.01 0.81 (0.67–0.97) 0.02 0.02
PR (CI)—model 1 0.81 (0.63–1.05) 0.12 0.20 0.98 (0.83–1.17) 0.83 0.95 0.64 (0.43–0.94) 0.02 0.01 0.82 (0.68–0.98) 0.03 0.03
PR (CI)—model 2 0.75 (0.59–0.95) 0.02 0.04 0.93 (0.79–1.11) 0.43 0.48 0.51 (0.34–0.76) 0.001 <0.001 0.79 (0.66–0.95) 0.01 0.01
Flavanones
Mean intake,
mg/day 185.3 vs. 16.6 180.4 vs. 16.8 179.8 vs. 17.6 183.6 vs. 15.3
Cases 90 vs. 74 211 vs. 203 48 vs. 53 179 vs. 184
PR
(CI)—unadjusted 1.22 (0.95–1.57) 0.11 0.37 1.04 (0.89–1.22) 0.59 0.47 0.92 (0.66–1.30) 0.65 0.67 0.98 (0.82–1.16) 0.80 0.47
PR (CI)—model 1 1.26 (0.98–1.62) 0.07 0.26 1.05 (0.90–1.23) 0.54 0.43 0.94 (0.67–1.33) 0.74 0.72 0.96 (0.81–1.14) 0.67 0.35
PR (CI)—model 2 1.05 (0.84–1.32) 0.66 0.86 0.98 (0.85–1.15) 0.84 0.93 0.82 (0.58–1.16) 0.26 0.24 0.92 (0.78–1.09) 0.35 0.12
Flavones
Mean intake,
mg/day 126.4 vs. 29.7 131.2 vs. 30.3 131.8 vs. 32.0 139.6 vs. 31.4
Cases 92 vs. 65 219 vs. 183 49 vs. 45 181 vs. 157
PR
(CI)—unadjusted 1.41 (1.08–1.83) 0.01 0.004 1.21 (1.03–1.42) 0.02 0.01 1.11 (0.78–1.59) 0.54 0.87 1.16 (0.96–1.39) 0.12 0.13
PR (CI)—model 1 1.42 (1.09–1.86) 0.01 0.003 1.22 (1.03–1.43) 0.02 0.009 1.16 (0.81–1.65) 0.43 0.69 1.18 (0.98–1.41) 0.08 0.08
PR (CI)—model 2 1.00 (0.78–1.29) 0.99 0.65 0.99 (0.84–1.16) 0.90 0.90 0.94 (0.66–1.34) 0.73 0.50 1.08 (0.90–1.31) 0.39 0.35
Flavonols
Mean intake,
mg/day 84.1 vs. 29.4 83.2 vs. 29.1 81.6 vs. 32.0 83.6 vs. 29.9
Cases 87 vs. 73 228 vs. 201 53 vs. 44 184 vs. 179
PR
(CI)—unadjusted 1.24 (0.96–1.60) 0.11 0.06 1.13 (0.97–1.32) 0.11 0.18 1.22 (0.86–1.73) 0.26 0.14 1.03 (0.87–1.23) 0.72 0.54
PR (CI)—model 1 1.25 (0.96–1.62) 0.10 0.05 1.13 (0.97–1.32) 0.12 0.21 1.27 (0.89–1.81) 0.11 0.09 1.09 (0.91–1.29) 0.34 0.25
PR (CI)—model 2 0.97 (0.76–1.23) 0.79 0.95 0.96 (0.83–1.12) 0.62 0.45 1.16 (0.82–1.64) 0.40 0.19 1.05 (0.89–1.25) 0.57 0.50
Anthocyanidins
Mean intake,
mg/day 94.9 vs. 13.9 97.6 vs. 13.3 82.0 vs. 11.8 87.5 vs. 10.1
Cases 67 vs. 73 224 vs. 174 47 vs. 47 172 vs. 185
PR
(CI)—unadjusted 0.93 (0.70–1.23) 0.60 0.29 1.29 (1.10–1.52) 0.002 0.005 1.02 (0.72–1.45) 0.90 0.93 0.93 (0.79–1.11) 0.44 0.28
PR (CI)—model 1 0.93 (0.70–1.23) 0.61 0.29 1.28 (1.09–1.51) 0.003 0.007 1.07 (0.75–1.54) 0.62 0.91 0.93 (0.79–1.11) 0.45 0.27
PR (CI)—model 2 0.80 (0.62–1.05) 0.14 0.02 1.10 (0.94–1.29) 0.22 0.30 0.89 (0.63–1.26) 0.50 0.32 0.93 (0.78–1.10) 0.38 0.24
Catechins
Mean intake, mg
/day 57.9 vs. 10.3 58.7 vs. 9.7 55.3 vs. 8.9 53.4 vs. 8.2
Cases 68 vs. 92 194 vs. 198 34 vs. 67 144 vs. 200
PR
(CI)—unadjusted 0.75 (0.58–0.97) 0.03 0.03 0.99 (0.84–1.17) 0.92 0.69 0.51 (0.36–0.73) 0.001 <0.001 0.72 (0.60–0.86) <0.001 <0.001
PR (CI)—model 1 0.76 (0.58–0.98) 0.03 0.04 1.01 (0.86–1.19) 0.88 0.52 0.53 (0.37–0.77) 0.001 0.002 0.75 (0.62–0.90) 0.002 0.002
PR (CI)—model 2 0.64 (0.51–0.81) <0.001 <0.001 0.91 (0.77–1.06) 0.23 0.50 0.48 (0.33–0.69) <0.001 <0.001 0.77 (0.64–0.92) 0.004 0.003
Antioxidants 2019, 8, 537 11 of 17
Table 3. Cont.
Men Women
Hydroxycinnamic
acids
Mean intake,
mg/day 435.3 vs. 122.3 457.0 vs. 127.2 407.2 vs. 123.6 426.1 vs. 125.7
Cases 97 vs. 63 244 vs. 180 45 vs. 50 195 vs. 174
PR
(CI)—unadjusted 1.54 (1.18–2.00) 0.001 0.003 1.36 (1.16–1.59) <0.001 <0.001 1.13 (0.80–1.61) 0.49 0.46 1.13 (0.95–1.33) 0.17 0.19
PR (CI)—model 1 1.52 (1.17–1.98) 0.002 0.005 1.35 (1.16–1.58) <0.001 <0.001 1.14 (0.81–1.62) 0.45 0.44 1.12 (0.94–1.33) 0.20 0.20
PR (CI)—model 2 1.62 (1.26–2.08) <0.001 <0.001 1.43 (1.23–1.66) <0.001 <0.001 1.15 (0.82–1.62) 0.41 0.40 1.16 (0.98–1.37) 0.08 0.09
Hydroxybenzoic
acids
Mean intake,
mg/day 30.7 vs. 6.5 31.7 vs. 5.8 24.2 vs. 5.2 22.3 vs. 4.2
Cases 72 vs. 78 208 vs. 197 38 vs. 59 149 vs. 191
PR
(CI)—unadjusted 0.93 (0.71–1.22) 0.61 0.32 1.06 (0.90–1.24) 0.48 0.36 0.65 (0.45–0.93) 0.02 0.02 0.78 (0.65–0.94) 0.008 0.005
PR (CI)—model 1 0.93 (0.71–1.22) 0.61 0.32 1.05 (0.89–1.23) 0.56 0.44 0.68 (0.47–0.97) 0.04 0.04 0.82 (0.68–0.99) 0.04 0.03
PR (CI)—model 2 0.76 (0.60–0.97) 0.03 0.01 0.92 (0.79–1.07) 0.28 0.34 0.62 (0.43–0.89) 0.01 0.01 0.83 (0.69–1.00) 0.05 0.04
Stilbenes
Mean intake,
mg/day 9.9 vs. 0.0 9.9 vs. 0.0 3.86 vs. 0.00 3.04 vs. 0.00
Cases 68 vs. 71 221 vs. 191 44 vs. 42 148 vs. 185
PR
(CI)—unadjusted 0.99 (0.74–1.31) 0.93 0.50 1.16 (0.99–1.36) 0.07 0.09 1.04 (0.72–1.52) 0.74 0.83 0.81 (0.67–0.97) 0.03 0.02
PR (CI)—model 1 0.99 (0.75–1.32) 0.97 0.54 1.16 (0.99–1.36) 0.07 0.09 1.10 (0.75–1.59) 0.55 0.63 0.83 (0.69–1.00) 0.05 0.04
PR (CI)—model 2 0.80 (0.61–1.05) 0.12 0.03 0.99 (0.84–1.16) 0.78 0.97 0.92 (0.61–1.37) 0.68 0.63 0.86 (0.70–1.06) 0.15 0.12
Lignans
Mean intake,
mg/day 2.20 vs. 1.00 2.22 vs. 1.00 2.12 vs. 1.33 2.15 vs. 1.00
Cases 71 vs. 75 221 vs. 207 44 vs. 47 156 vs. 197
PR
(CI)—unadjusted 0.93 (0.71–1.22) 0.61 0.52 1.06 (0.91–1.24) 0.44 0.71 0.95 (0.66–1.36) 0.77 0.61 0.80 (0.67–0.95) 0.012 0.005
PR (CI)—model 1 0.94 (0.66–1.24) 0.66 0.59 1.07 (0.91–1.25) 0.95 0.65 1.00 (0.69–1.45) 0.99 0.81 0.81 (0.68–0.97) 0.02 0.01
PR (CI)—model 2 0.70 (0.54–0.90) 0.005 0.004 0.88 (0.76–1.03) 0.06 0.04 0.88 (0.61–1.26) 0.47 0.34 0.77 (0.64–0.92) 0.004 0.002
Model 1—adjusted by age, education (basic studies, medium, high), smoking (never, former, smoker), physical activity (quintiles). Model 2—adjusted by the variables used in model 1 plus
total energy intake, consumption of refined cereals and animal products (from 17-point questionnaire) and of distilled beverages and liquors, sugar, soft drinks, cookies, and pastries (g/day).
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Hydroxycinnamic acids, however, were directly associated with T2D in both overweight and
obese men, showing a significant linear trend. Non-significant results were found for other polyphenol
groups, namely, flavanones, flavones, and flavonols, after adjusting for all potential confounders.
Nevertheless, it is worth mentioning that the intake of flavones was directly associated with T2D in
men in model 2, prior to adjustment for energy and dietary variables.
4. Discussion
In this baseline cross-sectional study within the PREDIMED-Plus trial, we observed that higher
intakes of some polyphenolic classes were inversely and lineally associated with the prevalence of T2D
in a population at high cardiovascular risk, and these associations depended on sex and BMI. We also
found that hydroxycinnamic acids were directly associated with T2D.
Previous epidemiological studies have investigated the association between intake of polyphenols
and T2D, but this is the first study that quantifies the association between the intake of different
polyphenol subgroups and T2D accounting for differences by sex and BMI.
In our study, catechins were the main source of flavan-3-ols because theaflavin intake was very
low. Together with proanthocyanidins, these compounds are classified as flavanols. The main sources
of flavanols in the PREDIMED-Plus cohort were cocoa and chocolate, apples, plums, red wine, and
tea. Proanthocyanidins and catechins were strongly and inversely associated with T2D in overweight
men and women, and obese women. In a previous longitudinal study conducted in a similar cohort
(PREDIMED study), proanthocyanidins and catechins showed the same association with new-onset
T2D when baseline glucose levels were taken out of the model but not in the fully adjusted model. In
a large, prospective, case-cohort study, Zamora-Ros et al. concluded that all flavan-3-ol monomers,
including catechins, as well as proanthocyanidins of low polymerization degree were associated with
a lower risk of developing T2D. As in our case, they did not find associations for flavonols, except for
myricetin intake [18].
Many studies have focused on other monomers of flavan-3-ols, especially epigallocatechin gallate,
usually found in tea, grapes, and some seeds, and chocolate catechins. The antidiabetic effects
of flavan-3-ols have been reported in animal and cell-culture studies, as well as several clinical
studies [4,19,20]. Data from a recent meta-analysis on cocoa intake and cardio-metabolic risk suggested
significant improvements on insulin-related outcomes [21].
Anthocyanidins are the blue, red, and purple pigments of most fruits and vegetables, such as
berries and wine. Although we only found an inverse linear trend with T2D in overweight men, results
from in vitro, animal, epidemiological, and human studies have suggested that anthocyanidins might
play an important role modulating T2D [20], even though they have low bioavailability. In the frame
of the EPIC-InterAct study, Zamora-Ros et al. did not find a significant association between dietary
anthocyanidins and incident T2D, which is in agreement with our findings [22]. However, Jennings et
al. found that higher anthocyanin and flavone intake, as well as anthocyanin-rich food consumption,
were associated with improvements of insulin resistance in a cross-sectional study with women [23],
and higher intakes of these colored compounds were also inversely associated with a lower risk of T2D
in the Nurses’ Health Study [24].
Hydroxybenzoic acids followed the same pattern as that of proanthocyanidins and catechins,
showing inverse associations in overweight men and women but not in obese men. Red wine,
olives, and walnuts were their principal sources in this cohort. Perhaps because they are the minor
components of the phenolic acid group, they have not received much attention in previous studies.
Hydroxycinnamic acids, on the other hand, accounted for more than 90% of the phenolic acid group,
coffee being the main food source. In our cohort, hydroxycinnamic acid intake was associated with
higher prevalence of T2D in men and almost in women. This result contradicts other studies regarding
coffee and their polyphenols, such as caffeic acid, or chlorogenic acid. Large observational studies have
pointed towards a significant inverse association between coffee consumption and T2D, especially
with decaffeinated coffee [25,26]. In a double-blind, placebo-controlled, cross-over design, Lane
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et al. concluded that caffeine impaired postprandial glucose metabolism, especially when caffeine
was ingested with carbohydrates. These results differ from those obtained with healthy subjects,
suggesting that caffeine, but not other compounds of coffee, could have negative consequences in
glucose homeostasis only in diabetics [27]. Our results support the notion that high caffeine intake
could be directly associated with T2D.
Stilbenes are non-flavonoid polyphenols, usually known due to its main
representative—resveratrol. Red wine is by far the main source of this group of compounds,
accounting for more than 90% of the intake. Stilbenes were strongly associated with lower odds of
developing T2D in the PREDIMED study [28]; however, we only found a mild association and a linear
trend for overweight man in the present cohort. It is worth mentioning that the intake of stilbenes
was three times higher in men than in women. More than 50% of women had less than 0.1 mg/day
of stilbenes. Clinical and animal models have described the antidiabetic effects of stilbenes [29,30].
Nevertheless, whether stilbenes are feasible for the prevention and/or management of T2D is still
controversial [31].
Lignans are phytoestrogens usually found in fiber-rich foods since they are constituents of plant
cell walls. In western populations, the consumption of lignans are usually greater than isoflavones.
The urinary excretion of lignan metabolites produced by the microbiota (mainly enterodiol and
enterolactone) is a marker for fiber intake and whole-grain products [32]. In our population, the main
source of lignans was virgin olive oil. Those in the highest quartile of lignan intake had lower odds
of having T2D except for overweight women where no association was found. These results agree
with the inverse association found a few years ago in the PREDIMED cohort [28]. Also in the same
line, lower T2D incidence was found in U.S. women with higher enterodiol and enterolactone in urine,
which are gut microbiota metabolites of dietary lignans [33]. However, Zamora-Ros et al. found no
significant associations between lignans and T2D incidence in the EPIC study [22].
We did not find significant associations with T2D prevalence for any of the following groups:
flavanones, flavones, and flavonols, although in a similar population, flavanones were inversely
associated with T2D incidence [28]. In a prospective study conducted in two female large cohorts,
urinary excretion of hesperetin (a flavanone) was related to a decreased risk of T2D after a long
follow-up. Other polyphenol metabolites, including naringenin, quercetin, isorhamnetin, and caffeic
acid, were only inversely associated in the short term [34]. Two large observational studies also support
the antidiabetic effects of flavonols [22,35].
We noticed that, in our population, prevalence ratios in overweight participants were generally
lower than in obese ones. These results agree with the fact that obesity is associated with lower
nutrient bioavailability. Novotny et al. conducted a pilot study to investigate the pharmacokinetic
response of grape polyphenols in overweight and obese vs. lean volunteers. They found higher
concentrations for catechin, epicatechin, quercetin, and resveratrol in individuals with normal BMI,
suggesting that obesity could compromise polyphenol absorption [6]. A previous randomized crossover
study with blackberries also reported that lean volunteers had better anthocyanin metabolism than
overweight/obese ones [5].
The exact mechanisms by which polyphenols affect T2D are still unknown. Several in vitro and
animal studies have pointed out that polyphenols decrease glucose absorption in the small intestine
due to the inhibition of α-glucosidase, α-amylase, and sucrase in the gut mucosa, and they also limit
their reabsorption in the kidney. Other mechanisms of action are related to peripheral tissues. That
includes inhibition of gluconeogenesis, adrenergic stimulation of glucose uptake, and stimulation of
insulin release by pancreatic β-cells [36].
The main limitation of the present study is the cross-sectional design, which does not allow
us to assess causality, but also the estimation of polyphenol intake through FFQs, so bioavailability
could not be considered. Furthermore, as in all epidemiological studies, residual confounding cannot
be excluded. Finally, these results might not be generalizable to other populations. Our study has
also several strengths, including the big sample size, the blinded assessment of the endpoint, the
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multicenter design, and the comprehensive data on dietary intake and risk factors of T2D and other
potential confounders.
Many research studies endorse the role of polyphenols in modulating the risk of diseases.
However, there are many issues to deal with when assessing these effects such as their wide variability
of structures, the difficulty of analyzing polyphenol content in foods, the interactions between them,
other food components and food matrices, and the complexity of the human body [37].
Authors should discuss the results and how they can be interpreted in the perspective of previous
studies and of the working hypotheses. The findings and their implications should be discussed in the
broadest context possible. Future research directions may also be highlighted.
5. Conclusions
We can conclude that high intakes of some polyphenols are inversely associated with the prevalence
of T2D in older adults with metabolic syndrome, these relationships being more especially observed in
overweight subjects than in obese ones. However, hydroxycinnamic acids are directly associated with
T2D. In that sense, randomized controlled trials would be useful to confirm the promising benefits of
polyphenols for the prevention and management of T2D.
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